Shots:

• The collaboration provides Charles River’s client access to Fios Genomics’ expertise in bioinformatics- statistics and biology- assisting the sourcing and analysis datasets associated with the drug development including microarrays- NGS- proteomics- metabolomics- epigenetics and associated meta-data
• The agreement merges Fios’ biologically-relevant insights with Charles River’s drug discovery and development platform and the scientific expertise of both the companies
• The focus of the agreement is to accelerate preclinical- discovery and development by turning complex data into actionable information. Charles River’s clients will be able to make data-driven decisions about their programs thus leading to an improvement in speed

Click here to­ read full press release/ article | Ref: Charles River | Image: Mayo news